STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what	2,3
		was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4,5,6
Objectives	3	State specific objectives, including any prespecified hypotheses	6,7
Methods			•
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of	7
		recruitment, exposure, follow-up, and data collection	,
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods	7,8
	Ü	of selection of participants. Describe methods of follow-up	,,0
		Case-control study—Give the eligibility criteria, and the sources and	
		methods of case ascertainment and control selection. Give the rationale for	
		the choice of cases and controls	
		Cross-sectional study—Give the eligibility criteria, and the sources and	
		methods of selection of participants	7.0
		(b) Cohort study—For matched studies, give matching criteria and number	7,8
		of exposed and unexposed	
		Case-control study—For matched studies, give matching criteria and the	
		number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders,	8,9
		and effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	9
measurement		assessment (measurement). Describe comparability of assessment methods	
		if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	7,8,
			11
Study size	10	Explain how the study size was arrived at	9,10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	10,1
-		applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	10,1
		confounding	,
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	NA
		(d) Cohort study—If applicable, explain how loss to follow-up was	NA
		addressed	11/1
		Case-control study—If applicable, explain how matching of cases and	
		controls was addressed	
		Cross-sectional study—If applicable, describe analytical methods taking	
		account of sampling strategy	3.7.1
		(\underline{e}) Describe any sensitivity analyses	NA

Results

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and	
data		information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	NA
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time	NA
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	NA
		Cross-sectional study—Report numbers of outcome events or summary measures	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	NA
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	NA
Generalisability	21	Discuss the generalisability (external validity) of the study results	NA
Other informati	on		
Funding 22		Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

^{*}Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.